




RealRate

PHARMACEUTICAL 2014

Ayala Pharmaceuticals Inc
Rank 203 of 234

ADVAXIS
IMMUNOTHERAPIES™



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Ayala Pharmaceuticals Inc is the variable Expenses, reducing the Economic Capital Ratio by 147% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 138% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	20,810
Cost of Goods Sold	0
Intangible Assets	2,529
Liabilities, Current	4,937
Liabilities, Non-Current	0
Other Assets	167
Other Compr. Net Income	0
Other Expenses	13,321
Other Liabilities	647
Other Net Income	15,278
Other Revenues	1,863
Property and Equipment	80
Research and Development	35,425
Selling, General and Administrative Expense	35,940

Output Variable	Value in 1000 USD
Assets	23,586
Liabilities	5,584
Expenses	84,686
Revenues	1,863
Stockholders Equity	18,002
Net Income	-67,544
Comprehensive Net Income	-67,544
BaseVar	65,499
ECR before Limited Liability	-194%
Economic Capital Ratio	104%